Search Tag: Sedaconda

ICU Management

Sedana Medical Applies for Market Approval in Italy

2021 22 Dec

Sedana Medical AB (publ) has announces that the company has submitted an application for market approval for Sedaconda (isoflurane) for inhaled sedation in intensive care in Italy. “With the application in Italy, we are hoping to bring our Sedaconda products to yet another important European market. Having received market approval in 14 European... Read more

ICU Management

SEDANA MEDICAL RECEIVES APPROVAL IN GERMANY

2021 28 Sep

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany. The approval applies to the drug Sedaconda (isoflurane) for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in Germany.... Read more

ICU Management

SEDANA MEDICAL RECEIVES APPROVAL IN FRANCE

2021 13 Aug

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in France. The approval applies to the drug Sedaconda (isoflurane)* for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in France.... Read more

ICU Management

Sedana Medical Receives Approval for European Dossier

2021 20 Jul

Sedana Medical AB (publ) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation of mechanically ventilated adult patients during intensive care and should only be administered via the medical device AnaConDa.... Read more